About the Global Campaign
In countries from the U.S. to Vietnam, Brazil to Indonesia, health groups are aiming to break Abbott’s monopoly control over lopinavir+ritonavir (Kaletra). Campaigners say Abbott’s high price for Kaletra is blocking expansion of AIDS treatment, and its anti-competitive practices are impeding new drug innovation.
Press Release (November 9, 2011)
English | Español | Chinese
"I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need." --Naza of Malaysia's PT Foundation
Return to the Kaletra Campaign Homepage